VolitionRx Limited (VNRX)
| Market Cap | 5.85M -85.5% |
| Revenue (ttm) | 3.44M +134.0% |
| Net Income | -24.62M |
| EPS | -2.40 |
| Shares Out | 36.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,206,889 |
| Open | 0.1611 |
| Previous Close | 0.1647 |
| Day's Range | 0.1558 - 0.1650 |
| 52-Week Range | 0.1554 - 7.7260 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | 11.78 (+7,167.12%) |
| Earnings Date | Nov 12, 2026 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s c... [Read more]
Financial Performance
In 2025, VolitionRx's revenue was $1.73 million, an increase of 40.04% compared to the previous year's $1.23 million. Losses were -$23.36 million, -13.39% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for VNRX stock is "Buy." The 12-month stock price target is $11.78, which is an increase of 7,167.12% from the latest price.
News
VolitionRx downgraded to Hold from Buy at Freedom Broker
Freedom Broker downgraded VolitionRx (VNRX) to Hold from Buy without a price target The firm says the company’s financing path remains uncertain. It cites “significant” expected dilution and VolitionR...
VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones
Peer-reviewed validation in sepsis, >95% early-stage cancer detection in a blinded cohort, a government-funded sepsis program in France, licensing discussions with more than a dozen diagnostic compani...
VolitionRx expands supply agreement with Fujifilm Vet Systems
VolitionRx (VNRX) announces the expansion of its supply agreement with Fujifilm Vet Systems Co. in Japan, allowing the development and use of the Nu.Q Vet Feline Test. Published first on…
Volition Expands Contract with Fujifilm to Include the Nu.Q® Vet Test for Cats
Expansion extends potential use of Nu.Q® technology to Japan's almost nine million cats Volition expects Nu.Q® Vet Feline Test to be the world's first simple, affordable blood-based liquid biopsy test...
VolitionRx Earnings Call Transcript: Q3 2026
Q3 revenue rose 157% YoY and operating loss narrowed 35%, while debt was sharply reduced. Commercialization efforts advanced across sepsis, cancer, and veterinary products, though revenue remains uneven and 2026 guidance was withheld.
VolitionRx Earnings release: Q3 2026
VolitionRx released its Q3 2026 earnings on November 13, 2026, summarizing the period's financial results.
VolitionRx Quarterly report: Q3 2026
VolitionRx has published its Q3 2026 quarterly earnings report on November 13, 2026.
VolitionRx reports Q3 revenue $1.6M, consensus $696.15K.
Reports Q3 net loss $3.8M vs. a net loss of $5.4M in the prior-year period. CEO Cameron Reynolds said, “It has been a very full quarter as we have continued…
VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update
Conference call to take place on Friday, November 13 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
VolitionRx signs LOI with Missionpharma for lateral flow technology for NETosis
VolitionRx (VNRX) has executed a non-binding Letter of Intent, or LOI, with Missionpharma A/S, a Danish global company in the filed of the sale and distribution of healthcare products and…
VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
HENDERSON, Nev., Oct. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of...
VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash
Reduces outstanding principal to only $0.7 million on the $2.4 million note and brings total debt reduction across both notes to over $5.0 million since June 30, 2026. Secures agreement pausing conver...
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ( XASE: VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Gov...
VolitionRx Participates in Launch of DETECSEPS Program in France
French Government-Funded €6.3 million (~$7.3 million) Consortium Selects Volition's Nu.Q® NETs Assay as Sole Biomarker for France's Real World Evaluation of Early Detection of Sepsis HENDERSON, Nev.,...
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
Reduces Equity Overhang HENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-paymen...
VolitionRx presents early stage I solid cancer detection at ESMO MAP Conference
VolitionRx (VNRX) announced the presentation of an abstract at the European Society of Medical Oncology Molecular Analysis for Precision Oncology Conference – ESMO MAP – in London this week. The…
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.
VolitionRx Slides: Corporate presentation
VolitionRx has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
VolitionRx Registration statement: Registration filing
VolitionRx filed a registration statement on September 9, 2026, providing details about a securities offering with the SEC.
VolitionRx Registration statement: Registration filing
VolitionRx filed a registration statement on September 8, 2026, providing details about a securities offering with the SEC.
VolitionRx files to sell 10.01M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 10.01M shares of common stock. The company is not selling any…
VolitionRx Registration statement: Registration filing
VolitionRx filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev.,...
VolitionRx announces publication on Nu.Q NETs H3.1 biomarker
VolitionRx (VNRX) announced the publication of a peer-reviewed paper and independent Editorial which reported that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and need...